160.81 -0.91 (-0.56%) | 05-02 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 201.92 | 1-year : | 212.92 |
Resists | First : | 172.88 | Second : | 182.3 |
Pivot price | 164.04 | |||
Supports | First : | 157.64 | Second : | 131.16 |
MAs | MA(5) : | 161.26 | MA(20) : | 165.35 |
MA(100) : | 168.29 | MA(250) : | 153.6 | |
MACD | MACD : | -3.2 | Signal : | -3 |
%K %D | K(14,3) : | 32 | D(3) : | 31.1 |
RSI | RSI(14): 35.9 | |||
52-week | High : | 182.88 | Low : | 130.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABBV ] has closed above bottom band by 22.6%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 162.25 - 163.35 | 163.35 - 164.25 |
Low: | 156.03 - 157.09 | 157.09 - 157.97 |
Close: | 159.24 - 160.98 | 160.98 - 162.42 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Fri, 03 May 2024
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.02 Per Share, Leerink Partnrs Forecasts - Defense World
Thu, 02 May 2024
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Wed, 01 May 2024
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Wed, 01 May 2024
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Zacks Investment Research
Tue, 30 Apr 2024
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript - Yahoo Finance
Mon, 29 Apr 2024
AbbVie: The Inevitable Is Happening (NYSE:ABBV) - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - General
|
|
Shares Out | 1,770 (M) |
Shares Float | 1,760 (M) |
Held by Insiders | 0.1 (%) |
Held by Institutions | 71.9 (%) |
Shares Short | 13,120 (K) |
Shares Short P.Month | 14,270 (K) |
EPS | 2.71 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 5.86 |
Profit Margin | 8.9 % |
Operating Margin | 31.8 % |
Return on Assets (ttm) | 8 % |
Return on Equity (ttm) | 35.2 % |
Qtrly Rev. Growth | -5.5 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 30.68 |
EBITDA (p.s.) | 14.89 |
Qtrly Earnings Growth | -67 % |
Operating Cash Flow | 22,840 (M) |
Levered Free Cash Flow | 22,630 (M) |
PE Ratio | 59.33 |
PEG Ratio | 2.3 |
Price to Book value | 27.39 |
Price to Sales | 5.23 |
Price to Cash Flow | 12.46 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |